Navigation Links
Onyx Pharmaceuticals Announces First Quarter 2010 Financial Results Teleconference and Webcast
Date:4/27/2010

EMERYVILLE, Calif., April 27 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to provide a general business overview, as well as to discuss first quarter 2010 financial results, on Tuesday, May 4, 2010, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).  Financial results for the first quarter ended March 31, 2010 will be released earlier that day.

Interested parties may access a live webcast of the presentation on the company's website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-619-6547 and using the passcode 26940268.  A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 26940268 approximately one hour after the teleconference concludes.  The replay will be available through May 18, 2010. 

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer.  The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer.  Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types.  Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors, and ONX 0801, a targeted alpha-folate inhibitor, currently in Phase 1 testing.  For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2017)... , June 30, 2017 In vitro ... the start of May, at least ten diagnostic companies ... private investments, public offerings and a loan facility.  The ... to almost $80 million.  Kalorama Information provides a monthly ... its Diagnostics Knowledge Center. ...
(Date:6/30/2017)... HIGH POINT, N.C. , June 29, 2017  Axium Pharmaceuticals ... innovations for developing improved novel formulations and alternative dosage forms ... ... transmucosal delivery is based on our waterless self-nano emulsifying formula, ... after contact with saliva. We believe the spray will provide ...
(Date:6/27/2017)... , Jun 27, 2017   NuEyes (NuEyes Technologies ... funding to fuel its growth in helping the legally blind ... (Osterhout Design Group), the leading developer of augmented, virtual and ... sits. The undisclosed funding amount was provided by ... Arab Angel, with offices in Abu Dhabi ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased to announce the ... July 17, 2017, Ms. Vu will join West Dermatology’s large network of medical and ... skin cancer , and more. She graduated from the University of Florida College ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... (ACL) offer patients improved quality of life five years after injury, according to ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five years ...
(Date:7/20/2017)... Viejo, CA (PRWEB) , ... July 20, 2017 , ... ... when placed between two clips in the FCPX timeline. This effect isolates horizontal and ... transition in this package contains either a rotating or flipping animation and can be ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) ... progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a ... relapse. With such a challenging diagnosis that requires immediate action, patients and ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... law firm headquartered in Houston, is pleased to announce their expansion to the ... affordable housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John ...
Breaking Medicine News(10 mins):